Literature DB >> 6486983

Nonseptic cerebral emboli of cardiac origin.

G J Martin, J Biller.   

Abstract

There is considerable debate regarding immediate anticoagulation with heparin sodium for patients suspected of having acute cerebral embolism from a cardiac source. We studied 60 consecutive hospitalized patients suspected of having a nonseptic cardiogenic cerebral embolism who, with one exception, were treated with immediate full-dose anticoagulation. None of the patients had progression of their neurologic deficits secondary to intracranial hemorrhage or recurrent embolism, and there were no deaths secondary to anticoagulant therapy. One patient had punctate hemorrhages in the area of infarction, but remained clinically stable. In light of our experience and a review of the literature, we conclude that immediate anticoagulation is judiciously safe in selected patients after nonseptic embolic stroke of cardiac origin, provided early cranial computed tomography fails to demonstrate hemorrhagic infarction.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6486983

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  4 in total

1.  Internal carotid artery occlusion in a young female with mitral valve prolapse.

Authors:  M A Saadah; R A Shakir; M A Rudwan; N Khan
Journal:  Postgrad Med J       Date:  1986-12       Impact factor: 2.401

2.  Cooperative study on the value of long term anticoagulation in patients with stroke and non-rheumatic atrial fibrillation.

Authors:  J Lodder; M S Dennis; L Van Raak; L N Jones; C P Warlow
Journal:  Br Med J (Clin Res Ed)       Date:  1988-05-21

Review 3.  Clinical evaluation and management of transient ischemic attacks.

Authors:  J F Rothrock
Journal:  West J Med       Date:  1987-04

4.  Anticoagulant therapy in recurrent cerebral embolism: a retrospective study in non-valvular atrial fibrillation.

Authors:  H Yamanouchi; H Nagura; Y Ohkawa; Y Sakurai; S Kuzuhara; K Kuramoto; H Shimada; Y Toyokura
Journal:  J Neurol       Date:  1988-09       Impact factor: 4.849

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.